HCA Healthcare, Inc. $HCA Shares Sold by ASR Vermogensbeheer N.V.

ASR Vermogensbeheer N.V. lowered its position in HCA Healthcare, Inc. (NYSE:HCA) by 0.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,359 shares of the company’s stock after selling 62 shares during the quarter. ASR Vermogensbeheer N.V.’s holdings in HCA Healthcare were worth $6,266,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of HCA. Price T Rowe Associates Inc. MD lifted its position in HCA Healthcare by 83.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,399,372 shares of the company’s stock valued at $829,104,000 after buying an additional 1,091,416 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in HCA Healthcare by 49.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,781,459 shares of the company’s stock valued at $615,583,000 after purchasing an additional 587,036 shares in the last quarter. Nuveen LLC purchased a new stake in shares of HCA Healthcare in the first quarter worth about $569,217,000. Pacer Advisors Inc. raised its holdings in shares of HCA Healthcare by 6,237.9% during the 1st quarter. Pacer Advisors Inc. now owns 1,350,933 shares of the company’s stock valued at $466,815,000 after buying an additional 1,329,618 shares during the period. Finally, Principal Financial Group Inc. grew its position in HCA Healthcare by 0.8% in the first quarter. Principal Financial Group Inc. now owns 880,663 shares of the company’s stock valued at $304,313,000 after acquiring an additional 6,888 shares in the last quarter. Hedge funds and other institutional investors own 62.73% of the company’s stock.

HCA Healthcare Price Performance

HCA stock opened at $426.81 on Friday. The firm has a fifty day moving average price of $395.62 and a two-hundred day moving average price of $371.70. HCA Healthcare, Inc. has a 1-year low of $289.98 and a 1-year high of $429.43. The firm has a market cap of $99.87 billion, a price-to-earnings ratio of 17.94, a PEG ratio of 1.34 and a beta of 1.40.

HCA Healthcare (NYSE:HCA) last released its quarterly earnings data on Friday, July 25th. The company reported $6.84 earnings per share for the quarter, topping the consensus estimate of $6.20 by $0.64. The firm had revenue of $18.61 billion for the quarter, compared to analyst estimates of $18.49 billion. HCA Healthcare had a net margin of 8.21% and a negative return on equity of 7,363.11%. HCA Healthcare’s quarterly revenue was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.50 earnings per share. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. As a group, analysts expect that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Tuesday, September 16th were issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend was Tuesday, September 16th. HCA Healthcare’s dividend payout ratio (DPR) is 12.11%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Barclays upped their target price on shares of HCA Healthcare from $390.00 to $445.00 and gave the company an “overweight” rating in a research note on Thursday, September 18th. Wolfe Research lowered HCA Healthcare from an “outperform” rating to a “peer perform” rating in a research report on Monday, July 28th. Wells Fargo & Company lowered their price objective on HCA Healthcare from $385.00 to $375.00 and set an “equal weight” rating for the company in a research note on Thursday, August 14th. JPMorgan Chase & Co. increased their target price on HCA Healthcare from $360.00 to $370.00 and gave the company a “neutral” rating in a research note on Monday, August 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $444.00 price target on shares of HCA Healthcare in a report on Tuesday, August 26th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, HCA Healthcare has a consensus rating of “Moderate Buy” and an average price target of $407.75.

Insider Transactions at HCA Healthcare

In other HCA Healthcare news, EVP Michael S. Cuffe sold 3,836 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $418.84, for a total value of $1,606,670.24. Following the completion of the transaction, the executive vice president owned 31,503 shares in the company, valued at approximately $13,194,716.52. This represents a 10.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is owned by insiders.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.